Paul Monk

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. pmc A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma
    Paul Monk
    Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University, and Arthur G James Cancer Hospital and Solove Research Institute, Columbus, OH Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, CO
    J Immunother 37:180-6. 2014
  2. doi request reprint Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782
    J Paul Monk
    Division of Oncology, Department of Medicine, The Ohio State University School of Medicine, Columbus, Ohio, USA
    Cancer 118:4139-47. 2012
  3. doi request reprint A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors
    J Paul Monk
    Ohio State University, Columbus, OH, USA
    Invest New Drugs 30:1676-83. 2012
  4. pmc Low grade papillary transitional cell carcinoma pelvic recurrence masquerading as high grade invasive carcinoma, ten years after radical cystectomy
    Pankaj P Dangle
    The James Cancer Hospital and Solove Research Institute, Ohio State University and Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    World J Surg Oncol 6:103. 2008
  5. ncbi request reprint A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors
    Ludmila K Martin
    Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, Columbus, OH, USA
    Onkologie 36:657-60. 2013
  6. ncbi request reprint Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies
    Padma Nadella
    Department of Medicine, Ohio State University College of Medicine and Public Health, Columbus, OH 43210 1240, USA
    J Clin Oncol 20:2616-23. 2002

Collaborators

Detail Information

Publications6

  1. pmc A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma
    Paul Monk
    Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University, and Arthur G James Cancer Hospital and Solove Research Institute, Columbus, OH Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, CO
    J Immunother 37:180-6. 2014
    ..HD IL-2 followed by sorafenib was safe and feasible in patients with MM and RCC and did not adversely affect T-cell signaling through STAT5 in response to IL-2...
  2. doi request reprint Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782
    J Paul Monk
    Division of Oncology, Department of Medicine, The Ohio State University School of Medicine, Columbus, Ohio, USA
    Cancer 118:4139-47. 2012
    ..Because testosterone levels are not suppressed, this approach may be associated with less morbidity than conventional gonadal androgen suppression...
  3. doi request reprint A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors
    J Paul Monk
    Ohio State University, Columbus, OH, USA
    Invest New Drugs 30:1676-83. 2012
    ..To determine the maximally tolerated dose (MTD) and pharmacokinetics of carboplatin plus KOS-862 (Epothilone D) a novel cytotoxic macrolide capable of causing mitotic arrest, in patients with advanced solid malignancies...
  4. pmc Low grade papillary transitional cell carcinoma pelvic recurrence masquerading as high grade invasive carcinoma, ten years after radical cystectomy
    Pankaj P Dangle
    The James Cancer Hospital and Solove Research Institute, Ohio State University and Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    World J Surg Oncol 6:103. 2008
    ..Tumor recurrence following radical cystectomy for a low-grade superficial transitional cell carcinoma (TCC) is exceedingly uncommon and has not been reported previously...
  5. ncbi request reprint A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors
    Ludmila K Martin
    Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, Columbus, OH, USA
    Onkologie 36:657-60. 2013
    ....
  6. ncbi request reprint Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies
    Padma Nadella
    Department of Medicine, Ohio State University College of Medicine and Public Health, Columbus, OH 43210 1240, USA
    J Clin Oncol 20:2616-23. 2002
    ..We hypothesized that weekly docetaxel would result in sustained dThdPase expression and that capecitabine administration at times of maximum dThdPase upregulation would increase the therapeutic index for this combination...